{"id":"W2891362692","doi":"10.1200/jco.2018.36.15_suppl.5514","title":"QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; BRCA mutation; Phases of clinical research; Ovarian cancer; Population; Oncology; Chemotherapy; Progressive disease; Refractory (planetary science); Adverse effect; Gastroenterology; Placebo; Cancer; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001087514,0.001076543,0.001417616,0.0003291709,0.0002448418,0.0007013511,0.0008226077,0.0007582848,0.005490664],"category_scores_gemma":[0.0006065591,0.0005019258,0.001006135,0.0002880207,0.0005548804,0.0006833773,0.0004535143,0.001907869,0.0008295805],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007238486,"about_ca_system_score_gemma":0.001191049,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004697317,"about_ca_topic_score_gemma":0.00177335,"domain_scores_codex":[0.9997576,0.0001166289,0.00001371414,0.00004674378,0.00002709412,0.00003822105],"domain_scores_gemma":[0.9995514,0.00005279183,0.0001182627,0.00003021449,0.00002532028,0.000222009],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7492809,0.0768626,0.01529606,0.001685707,0.001515743,0.000432949,0.0002091369,0.002366028,0.04152909,0.0003936072,0.006054196,0.104374],"study_design_scores_gemma":[0.5789891,0.3912366,0.02149732,0.00005374679,0.0004163794,0.0006495884,0.00005057676,0.001492246,0.001743028,0.0002480109,0.003590711,0.00003276149],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873366,0.002285373,0.0006859553,0.0004686191,0.00009934189,0.004091551,0.002518739,0.0001456109,0.002368281],"genre_scores_gemma":[0.9814218,0.001974679,0.002360754,0.001393148,0.0001505648,0.00450866,0.004550774,0.00003864133,0.003600831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005490664,"threshold_uncertainty_score":0.01836807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2181040717713145,"score_gpt":0.529958972689591,"score_spread":0.3118549009182765,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}